Rasmussen encephalitis: diagnostic and therapeutic approaches

Encefalitis de Rasmussen diagnóstico y enfoque terapéutico

Article Sidebar


PDF (Español (España)) FLIP HTML (Español (España)) XML (Español (España)) EPUB (Español (España)) AUDIO (mp3) (Español (España))

How to Cite
Espinosa, E., Fuentes, A., & Naranjo, A. L. (2019). Rasmussen encephalitis: diagnostic and therapeutic approaches. Journal of Medicine and Surgery Repertoire, 28(2). https://doi.org/10.31260/RepertMedCir.v28.n2.2019.922
Published: May 24, 2019
Doi
https://doi.org/10.31260/RepertMedCir.v28.n2.2019.922
Issue
Vol. 28 No. 2 (2019): Mayo - Agosto
Section
Case Reports
License terms

   

Main Article Content

Eugenia Espinosa
Angélica Fuentes
Amanda Liliana Naranjo

Abstract

Objective: to describe the case of a school-age patient aged 5 years 9 months diagnosed with acute Rasmussen encephalitis (RE), and its therapeutic approach. Case presentation: a girl aged 5 years 9 months presenting with progressive dystonic postures starting in the left lower limb with spread to the ipsilateral upper limb associated with focal seizures characterized by opercular epilepsy semiology which lead to status epilepticus. Cerebral magnetic resonance imaging revealed progressive structural changes with atrophy of the right cerebral hemisphere and basal nuclei. Anti-epileptic and immunmodulator therapy was initiated obtaining good response. Discussion: a review of the literature on RE clinical presentation, diagnosis and best treatment options was conducted. Conclusions: this is the case of a young girl with Rasmussen syndrome in the acute stage evidencing proper clinical progression after receiving immunotherapy. Few reports exist on this topic in Colombia. Our purpose was to present a case and review RE diagnostic and therapeutic approaches.

Keywords:

Downloads

Download data is not yet available.

Article Details

References

1. Bien CG, Granata T, Antozzi C, Cross JH, Dulac O, Kurthen M, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain. 2005;128(Pt 3):454-71.
2. Varadkar S, Bien CG, Kruse CA, Jensen FE, Bauer J, Pardo CA, et al. Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol. 2014;13(2):195-205.
3. Dupont S, Gales A, Sammey S, Vidailhet M, Lambrecq V. Late-onset Rasmussen Encephalitis: A literature appraisal. Autoimmun Rev. 2017;16(8):803-10.
4. Paas Y. The pathophysiological mechanism underlying Rasmussen's encephalitis: a debate. Trends Neurosci. 1998;21(11):468-9.
5. Freeman JM. Rasmussen's syndrome: progressive autoimmune multi-focal encephalopathy. Pediatr Neurol. 2005;32(5):295-9.
6. Mameniskiene R, Wolf P. Epilepsia partialis continua: A review. Seizure. 2017;44:74-80.
7. Granata T, Andermann F. Rasmussen encephalitis. Handb Clin Neurol. 2013;111:511-9.
8. Bien CG, Urbach H, Deckert M, Schramm J, Wiestler OD, Lassmann H, et al. Diagnosis and staging of Rasmussen's encephalitis by serial MRI and histopathology. Neurology. 2002;58(2):250-7.
9. Bahi-Buisson N, Nabbout R, Plouin P, Bulteau C, Delalande O, Hertz Pannier L, et al. [Recent advances in pathogenic concepts and therapeutic strategies in Rasmussen's encephalitis]. Rev Neurol. 2005;161(4):395-405. Avancees actuelles sur les concepts pathogeniques et therapeutiques de l'encephalite de Rasmussen.
10. Dubeau F, Sherwin AL. Pharmacologic principles in the management of chronic focal encephalitis. In: Rasmussen T, editor. Chronic Encephalitis and Epilepsy: Rasmussen's Syndrome Boston: Butterworth-Heinemann; 1991. p. 179-92.
11. Hart YM, Cortez M, Andermann F, Hwang P, Fish DR, Dulac O, et al. Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients. Neurology. 1994;44(6):1030-6.
12. Browner N, Azher SN, Jankovic J. Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis. Mov Disord. 2006;21(9):1500-2.
13. Lozsadi DA, Hart IK, Moore AP. Botulinum toxin A improves involuntary limb movements in Rasmussen syndrome. Neurology. 2004;62(7):1233-4.
14. Thilo B, Stingele R, Knudsen K, Boor R, Bien CG, Deuschl G, et al. A case of Rasmussen encephalitis treated with rituximab. Nat Rev Neurol. 2009;5(8):458-62.
15. Laxer K, Wilfong A, Morris GL, Andermann F. Pilot study of Rituximab to treat chronic focal encephalitis. Epilepsia. 2008;49(Supp. 7):121.
16. Grujic J, Bien CG, Pollo C, Rossetti AO. Vagus nerve stimulator treatment in adult-onset Rasmussen's encephalitis. Epilepsy Behav. 2011;20(1):123-5.
17. San-Juan D, Calcaneo Jde D, Gonzalez-Aragon MF, Bermudez Maldonado L, Avellan AM, Argumosa EV, et al. Transcranial direct current stimulation in adolescent and adult Rasmussen's encephalitis. Epilepsy Behav. 2011;20(1):126-31.
18. Bien CG, Tiemeier H, Sassen R, Kuczaty S, Urbach H, von Lehe M, et al. Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins. Epilepsia. 2013;54(3):543-50.
19. Hoffman CE, Ochi A, Snead OC, 3rd, Widjaja E, Hawkins C, Tisdal M, et al. Rasmussen's encephalitis: advances in management and patient outcomes. Childs Nerv Syst. 2016;32(4):629-40.
20. Althausen A, Gleissner U, Hoppe C, Sassen R, Buddewig S, von Lehe M, et al. Long-term outcome of hemispheric surgery at different ages in 61 epilepsy patients. 2013;84(5):529-36.

Citado por